Sun Pharma Q1FY26: profit falls 20%, revenue up 9%

Key takeaway from the June-quarter print

Sun Pharmaceutical Industries Ltd reported a mixed set of quarterly numbers for the period labelled Jun 25, with revenue rising year-on-year but profitability falling sharply. The data shared alongside the results highlights that total revenue increased to ₹13,851.40 crore versus ₹12,652.75 crore in the comparable period, while net income declined to ₹2,278.63 crore versus ₹2,835.62 crore.

The company’s updates also included dividend timelines, trading window restrictions, and a schedule of analyst and institutional investor interactions. For investors tracking Sun Pharma, the combination of a revenue uptick and a profit decline makes the expense and operating trend lines important to read alongside the headline numbers.

Q1 results snapshot: revenue up, profit down

For the fiscal period Jun 25, Sun Pharma reported:

• Total revenue: ₹13,851.40 crore (vs ₹12,652.75 crore; +9.47% YoY) and (vs ₹14,611.79 crore; -6.89% QoQ)
• Net income: ₹2,278.63 crore (vs ₹2,835.62 crore; -19.64% YoY) and (vs ₹2,714.03 crore; -5.99% QoQ)
• Operating income: ₹2,554.07 crore (vs ₹3,002.94 crore; -14.95% YoY) and (vs ₹2,751.98 crore; -6.45% QoQ)

A separate summary line in the provided material also states that revenue from operations increased by 10% to ₹13,786 crore, while consolidated net profit fell about 20% YoY to ₹2,278 crore. The quarterly table lists total revenue at ₹13,851.40 crore for the same period.

Expenses and margins: what the cost line shows

The June-quarter data shows higher costs year-on-year across several line items:

• Total operating expense rose to ₹11,297.33 crore from ₹9,649.81 crore (+17.07% YoY).
• Selling, general and admin (SG&A) increased to ₹2,801.66 crore from ₹2,454.62 crore (+14.14% YoY).
• Depreciation and amortisation moved up to ₹700.55 crore from ₹655.13 crore (+6.93% YoY).

While revenue grew year-on-year, the operating income and net income declines suggest that cost growth outpaced the topline increase in the period captured by this table.

QoQ comparison: sequential softening from the Mar 26 quarter

The note attached to the results states that the comparison is on a QoQ basis. On that basis, the Jun 25 period showed a sequential decline versus Mar 26 in key profitability measures:

• Operating income: ₹2,554.07 crore vs ₹2,751.98 crore
• Net income: ₹2,278.63 crore vs ₹2,714.03 crore
• Net income before taxes: ₹3,172.77 crore vs ₹3,551.34 crore

At the same time, some expense lines reduced sequentially in the table, such as other operating expenses total at ₹4,162.36 crore versus ₹5,322.84 crore.

Q4 FY26 context from the company’s audited results

Sun Pharma’s board, at its meeting on May 22, 2026, approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. For the quarter ended March 31, 2026, the provided consolidated metrics were:

• Consolidated revenue: ₹14,611.8 crore vs ₹12,958.8 crore (+12.8% YoY)
• EBITDA: ₹3,954.2 crore vs ₹3,354.4 crore (+17.9% YoY)
• PAT: ₹2,714.0 crore vs ₹2,149.9 crore (+26.2% YoY)
• EBITDA margin: 27.1% vs 25.9%, up 118 bps

This context matters because it shows the company delivered stronger year-on-year growth in the March 2026 quarter, before the YoY profit decline indicated in the June-quarter table.

Dividend: record date and payment timeline

Sun Pharma’s board recommended a final dividend of ₹5 per equity share for FY 2025-26, subject to shareholder approval. The company also disclosed the key dates:

• Record date: Tuesday, July 07, 2026
• Payment timeline: on or before Friday, August 07, 2026, if approved at the AGM

The material also lists past dividend references, including an ex-dividend date of Feb 05, 2026 for 11 INR, and an earlier ex-dividend date of Jul 07, 2025 for 5.5 INR.

Trading window closure: compliance update

The company stated that the trading window for dealing in company shares will close from July 01, 2026. It will remain closed until 48 hours after the declaration of unaudited financial results for the quarter ended June 30, 2026. Such disclosures are typically part of governance and compliance processes around results announcements.

Investor and analyst meetings: June conference schedule

Sun Pharma announced a schedule of analyst and institutional investor meetings on June 1, 2, and 4, 2026, in Mumbai. The listed events include:

• BofA India Conference 2026
• Morgan Stanley’s India Investment Forum 2026
• Citi India Conference 2026

The company also confirmed that no Unpublished Price Sensitive Information (UPSI) will be disclosed at these meetings. Separately, it announced another analyst or institutional meeting on May 27, 2026, with 360 ONE Capital (B&K) at the 16th Annual Investor Conference - TRINITY INDIA 2026 in Mumbai.

Stock price snapshots mentioned in the update

The material includes multiple price references from different timestamps:

• A BSE screen value showing 1938.85, up +50.90, with a “Today, 04:01 PM” reference.
• Another line stating: Sun Pharma share price is ₹1,888.20 as on 08 Jul, 2026, 03:56 PM IST.

These indicate that the market price cited in the source varied by the timestamp shown.

Summary table: June-quarter metrics in one place

Market impact: what the numbers signal

The June-quarter dataset points to a clear divergence between topline growth and bottom-line pressure on a year-on-year basis. Revenue growth of 9.47% YoY in the table was accompanied by -14.95% YoY operating income and -19.64% YoY net income. The expense lines shown, including total operating expense (+17.07% YoY) and SG&A (+14.14% YoY), provide a factual basis for why profitability metrics were weaker in this specific period.

The price references included in the source suggest the stock was being tracked closely around corporate actions and disclosures, including dividend record dates and upcoming results-related compliance windows. However, the provided material does not attribute any single price move to a specific event.

Analysis: why investors may focus on costs and timelines

From the numbers provided, the key analytical question is not revenue growth alone but the pace and composition of costs relative to sales. When operating expenses rise faster than revenue in the same comparable window, operating income can compress even if topline is improving. The QoQ declines in operating income and net income versus the period labelled Mar 26 also highlight sequential moderation in profitability within the table.

On corporate actions, the confirmed ₹5 final dividend and the disclosed record date (July 07, 2026) provide a clear near-term calendar item for shareholders. In parallel, the trading window closure from July 01, 2026 until 48 hours after the unaudited result declaration for the quarter ended June 30, 2026 is another timeline-driven item that investors and insiders typically track closely.

Conclusion: mixed quarter, clear corporate calendar

Sun Pharma’s June-quarter numbers showed higher revenue but lower profit on a year-on-year basis in the figures shared, alongside softer sequential profitability versus the period labelled Mar 26. The company has also set clear corporate dates around its final dividend (₹5 per share) and compliance timelines for the upcoming unaudited results. The next confirmed milestones in the material include the dividend payment timeline (if approved at the AGM) and the upcoming unaudited financial results process for the quarter ended June 30, 2026.